Notch | $15,000,000 | (Oct 2, 2025)
Clarifeye | $4,693,900 | (Oct 2, 2025)
Ankored | $4,000,000 | (Oct 2, 2025)
Certified by Founder
Lodge
OrsoBio
start up
United States
- Palo Alto, CA
- 08/11/2023
- Series A
- $60,000,000
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
- Industry Biotechnology Research
- Website https://orsobio.com/
- LinkedIn https://www.linkedin.com/company/orsobio/about/
Prosper AI | $5,000,000 | (Oct 2, 2025)
Gelt | $13,000,000 | (Oct 2, 2025)
Returnalyze | $6,000,000 | (Oct 2, 2025)
Hupside | $1,700,000 | (Oct 2, 2025)
Athernal Bio | $4,718,630 | (Oct 2, 2025)
Price.com | $12,000,000 | (Oct 2, 2025)
Mondoo | $17,500,000 | (Oct 2, 2025)
SolidCore.ai | $4,000,000 | (Oct 2, 2025)
Phaidra | $50,000,000 | (Oct 2, 2025)